WuXi Biologics (Cayman) Inc. reported no changes to its share structure or treasury shares in February 2026. Authorized share capital remained at US$50,000, representing 6,000,000,000 ordinary shares at a par value of US$0.00000833 each. The total number of issued shares stayed at 4.14 billion, while no treasury shares were held.

The company confirmed that public float remains in compliance with the 15.00% threshold. The pre-IPO share option scheme carried 32.20 million outstanding share options with no new issuances. In addition, 63.69 million shares may be issued under a restricted share award scheme, and 9.23 million shares may be issued under a share award scheme for the Global Partner Program. No new shares were issued or cancelled during the month.